Esperion drug succeeds in lowering LDL cholesterol -study
October 01, 2014 at 16:05 PM EDT
Oct 1 (Reuters) - A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.
